Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy

被引：18

作者：

Takamatsu, Kimillaru ^{[1
]}

Mizuno, Ryuichi ^{[1
]}

Omura, Minami ^{[1
]}

Morita, Shinya ^{[1
]}

Matsumoto, Kazuhiro ^{[1
]}

Shinoda, Kazunobu ^{[1
]}

Kosaka, Takeo ^{[1
]}

Takeda, Toshikazu ^{[1
]}

Shinojima, Toshiaki ^{[1
]}

Kikuchi, Eiji ^{[1
]}

Asanuma, Hiroshi ^{[1
]}

Oyama, Masafumi ^{[3
]}

Mikami, Shuji ^{[2
]}

Oya, Mototsugu ^{[1
]}

机构：

[1] Keio Univ Hosp, Dept Urol, Tokyo, Japan

[2] Keio Univ Hosp, Div Diagnost Pathol, Tokyo, Japan

[3] Saitama Med Univ, Dept Urooncol, Int Med Ctr, Hidaka, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2018年 / 16卷 / 04期

关键词：

Biomarker; International Metastatic Renal Cell Carcinoma Database Consortium Model; Kidney cancer; Molecular targeted drug; Prognosis; INTERFERON-ALPHA; CANCER; IMPACT; INFLAMMATION; SUNITINIB; SURVIVAL;

D O I：

10.1016/j.clgc.2018.03.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because accumulating evidence underlines the association of systemic inflammation with metastatic renalcell carcinoma (mRCC) progression, we evaluated baseline C-reactive protein (CRP) levels as a prognostic marker in 107 intermediate-risk mRCC patients treated with first-line targeted therapy. Baseline CRP could be a biomarker correlated with overall survival in the intermediate-risk group. Its cost efficacy and availability make CRP a helpful tool for reclassifying the intermediate-risk group. Background: Almost half of patients with metastatic renal-cell carcinoma (mRCC) are classified as intermediate risk by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The aim of this study was to evaluate whether baseline C-reactive protein (CRP) levels predict overall survival (OS) in intermediate-risk group mRCC patients. Patients and Methods: Data from 107 intermediate-risk group mRCC patients receiving first-line targeted therapy were retrospectively reviewed. We evaluated the correlation between baseline CRP levels as well as other indices and OS. Results: Of the 107 patients with intermediate-risk disease, 46 patients (43%) were classified as having elevated CRP levels. The elevation of pretreatment serum CRP levels was the independent prognostic factor of OS in patients with intermediate risk (hazard ratio, 4.609; P = .001). The 1- and 3-year survival rates of patients with intermediate-nonelevated CRP were 90.0% and 64.7% compared to the favorable-risk group, at 92.1% and 68.5%, respectively. In contrast, the 1 - and 3-year survival rates of patients with intermediate-elevated CRP were 80.5% and 37.4% compared to the poor-risk group, at 65.2% and 24.2%, respectively. Conclusion: Baseline CRP levels could divide mRCC patients in the intermediate-risk group into 2 prognostic subgroups.

引用

收藏

页码：E927 / E933

页数：7

相关论文

共 47 条

[31] Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy [J].

Choueiri, Toni K. ;

Regan, Meredith M. ;

Rosenberg, Jonathan E. ;

Oh, William K. ;

Clement, Jessica ;

Amato, Angela M. ;

McDermott, David ;

Cho, Daniel C. ;

Atkins, Michael B. ;

Signoretti, Sabina .

BJU INTERNATIONAL, 2010, 106 (06) :772-778

[32] The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma [J].

Shin, Su-Jin ;

Jeon, Yoon Kyung ;

Cho, Yong Mee ;

Lee, Jae-Lyun ;

Chung, Doo Hyun ;

Park, Ji Young ;

Go, Heounjeong .

ONCOLOGIST, 2015, 20 (11) :1253-1260

[33] Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail [J].

Malouf, Gabriel G. ;

Flippot, Ronan ;

Khayat, David .

JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (05) :412-+

[34] Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy [J].

Ishihara, Hiroki ;

Takagi, Toshio ;

Kondo, Tsunenori ;

Tachibana, Hidekazu ;

Yoshida, Kazuhiko ;

Omae, Kenji ;

Iizuka, Junpei ;

Kobayashi, Hirohito ;

Tanabe, Kazunari .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) :559-567

[35] Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor [J].

Sacre, Anne ;

Barthelemy, Philippe ;

Korenbaum, Clement ;

Burgy, Mickael ;

Wolter, Pascal ;

Dumez, Herlinde ;

Lerut, Evelyne ;

Loyson, Tine ;

Joniau, Steven ;

Oyen, Raymond ;

Debruyne, Philip R. ;

Schoffski, Patrick ;

Beuselinck, Benoit .

ACTA ONCOLOGICA, 2016, 55 (03) :329-340

[36] Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy? [J].

Korkmaz, Mustafa ;

Eryilmaz, Melek K. ;

Kocak, Mehmet Z. ;

Er, Muhammed M. ;

Hendem, Engin ;

Demirkiran, Aykut ;

Araz, Murat ;

Karaagac, Mustafa ;

Artac, Mehmet .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) :S160-S165

[37] C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma [J].

Klumper, Niklas ;

Schmucker, Philipp ;

Hahn, Oliver ;

Hoh, Benedikt ;

Mattigk, Angelika ;

Banek, Severine ;

Ellinger, Jorg ;

Heinzelbecker, Julia ;

Sikic, Danijel ;

Eckstein, Markus ;

Strauss, Arne ;

Zengerling, Friedemann ;

Holzel, Michael ;

Zeuschner, Philip ;

Kalogirou, Charis .

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (12)

[38] The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line [J].

Korkmaz, Mustafa ;

Eryilmaz, Melek Karakurt ;

Kocak, Mehmet Zahid ;

Er, Muhammed Muhiddin ;

Hendem, Engin ;

Demirkiran, Aykut ;

Araz, Murat ;

Artac, Mehmet .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (06) :941-947

[39] Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience [J].

Matrana, Marc R. ;

Bathala, Tharakeswara ;

Campbell, Matthew T. ;

Duran, Cihan ;

Shetty, Aditya ;

Teegavarapu, Purnima ;

Kalra, Sarathi ;

Xiao, Lianchun ;

Atkinson, Bradley ;

Corn, Paul ;

Jonasch, Eric ;

Tannir, Nizar M. .

BJU INTERNATIONAL, 2016, 118 (02) :264-271

[40] Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors [J].

Schuettke, Vayda ;

Kusiek, Cathrin ;

Fuessel, Susanne ;

Thomas, Christian ;

Buerk, Bjoern Thorben ;

Erdmann, Kati .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (05) :1117-1128

← 1 2 3 4 5 →